Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

FDA tentatively approves generic selexipag as PAH treatment

The U.S. Food & Drug Administration (FDA) has tentatively approved Alembic Pharmaceuticals‘ generic formulation of injectable selexipag as a treatment for pulmonary arterial hypertension (PAH). As a generic drug, which contains the same chemical substance as an approved treatment, it’s equivalent to Uptravi (selexipag) for injection (1,800…

Trial enrollment begins to test long-acting relaxin formula in PH-HFpEF

Enrollment has begun in a Phase 1b study of Tectonic Therapeutic’s TX45, an investigational treatment for people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). TX45 is a long-acting formulation of relaxin, a protein involved in reproduction and cardiovascular function. It has anti-fibrotic, or anti-scarring,…

FDA delays decision on extending Yutrepia to treat PH-ILD

Note: This story was updated Jan. 30, 2024, to correct the approved indications of available treprostinil formulations. The U.S. Food and Drug Administration (FDA) has delayed its decision to extend the use of Yutrepia — Liquidia‘s inhaled dry powder formulation of treprostinil — to people with…

Widening of the pulmonary artery in PH is common: Large-scale study

Pulmonary arterial dilatation — the abnormal widening of the main pulmonary artery leading from the heart — was a common feature among people with pulmonary hypertension (PH) in a large-scale study. The clinical characteristics related to a dilated pulmonary artery, such as heart function and blood flow parameters, varied widely…

Early study of inhaled nitric oxide delivery system doses 1st patient

An early feasibility study evaluating Third Pole Therapeutics‘ eNOfit — a miniaturized, portable inhaled nitric oxide (iNO) delivery system to treat pulmonary hypertension (PH) associated with interstitial lung disease — has dosed its first patient, the company announced. The goal for the investigational device is to provide patients…

HDL component ApoA-I predicts mortality in PAH: Study

Lower levels of apolipoprotein A-I (ApoA-I), a component of high-density lipoprotein (HDL), or “good cholesterol,” is a significant predictor of mortality in people with pulmonary arterial hypertension (PAH), a study suggests. “Our study identified the significance of ApoA-I as a biomarker for predicting the survival outcome of PAH patients,”…


A Conversation With Rare Disease Advocates